Core Viewpoint - Sanxin Medical has recently obtained EU MDR certification for its product, which may enhance its market access in Europe and positively impact future international business, although actual sales are subject to regulatory and market environment constraints [2] Recent Events - The EU MDR certification was granted on January 29, 2026, for the "single-use sterile dialysis care package," which is expected to improve the company's entry conditions in the EU market [2] Fund Movements - On January 30, 2026, Sanxin Medical's stock price increased by 2.39%, but there was a net outflow of main funds amounting to 1.1131 million yuan, with a cumulative decline of 1.87% over the past five days. This indicates a divergence in short-term market sentiment [3] - On January 8, 2026, main funds saw a net inflow of 12.2415 million yuan, with a cumulative inflow of 19.8708 million yuan over the past five days, driven by the enthusiasm in the medical device sector, but frequent fund inflow and outflow reflect cautious sentiment in the short term [3] Industry Policy and Environment - The medical device sector benefits from demographic aging, upgraded medical demand, and expectations of industrial internet policies. Sanxin Medical's valuation is at a medium level within the industry, with a TTM price-to-earnings ratio of approximately 19.37 times. The company's Q3 2025 report shows revenue and net profit growth, but attention is needed on industry competition, procurement policy changes, and performance realization pace [4] Shareholder Situation - As of September 30, 2025, the number of shareholders increased to 23,100, a rise of 26.57% compared to the previous period. Institutional investors, such as Dacheng Fund, have entered the top ten circulating shareholders. The increase in shareholder numbers may lead to greater dispersion of shares, potentially affecting stock price stability [5]